Cargando…

中国易瑞沙扩大用药项目中晚期非小细胞肺癌长期生存患者的研究

BACKGROUND AND OBJECTIVE: The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary obj...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000305/
https://www.ncbi.nlm.nih.gov/pubmed/22681919
http://dx.doi.org/10.3779/j.issn.1009-3419.2012.06.03